Recent study investigated mother-to-child transmission (MTCT) rates of hepatitis B virus (HBV) in infants born to ...

The ability of A2-derived HBV vaccines to protect against non-A2 HBV genotypes has recently been brought into question following the publication of a study of 3.7 million blood donors in the USA.

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

Chronic HBV was associated with increased risk for adverse COVID-19 outcomes, but the risk was lower among coinfected patients vaccinated against COVID-19.

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Introduction: Infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is a public health problem ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.